RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M

RxSight, Inc.

2024-Q3 EPS reported -$0.56 revenue$99,713,000

Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).
Gross margin 71.4% vs 61.9% YoY; net loss narrowed to $6.3M ($0.16/sh) from $12.4M ($0.35/sh).
Adjusted net earnings $214K ($0.00/diluted) vs adjusted loss $6.9M ($0.19/sh) a year ago.
FY2024 revenue guidance raised to $139-140M top of prior range; gross margin guided 70-71% (up from 68-70%).
Cash & equivalents $237.1M at Sept 30, 2024 vs $233.3M at June 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.